As BRAFV600E is the most frequent mutation in melanoma [3, 22, 23], and BRAF and RAS oncogenes were described as potential inducers of NRF2 [24], we tested the effect of BRAFV600E expression on NRF2 in melanocytes. This evidence concerns the gene NFE2L2 and melanoma.